Cell Death Discovery
ApoA2 promotes tumor metastasis and drug resistance in hepatocellular carcinoma by activating the HMGB1/IL-17A axis
Abstract Anti-angiogenic therapy is a standard first-line treatment for advanced hepatocellular carcinoma (HCC), but drug resistance remains a major obstacle to its long-term efficacy. Our previous study found that apolipoprotein A2 (ApoA2) was highly expressed in anti-angiogenic drug-resistant HCC. However, the mechanism underlying ApoA2-mediated resistance to anti-angiogenic therapy remains unclear. Here, ApoA2 overexpression markedly promoted HCC cell proliferation, inhibited lenvatinib-induced apoptosis in vitr …